Abstract:AT-Rich Interacting Domain 1A (ARID1A) is an important component in SWI/SNF Complex, a chromatin remodeller and an established tumor suppressor gene that is mutated in a variety of cancer types. This includes endometrial (~45%), bladder (~20%), and gastric (~15%). ARID1A mutations usually lead to a loss of protein expression or function, which results in tumor progression. The loss of ARID1A has been linked to genomic instability, potentially making the tumor more immunogenic/amenable to immune checkpoint inhibitor therapy. However, there is a discrepancy between clinical and mechanistic studies in determining the consequence of ARID1A-loss on the tumor immune microenvironment (TIME): clinical studies have shown that ARID1A mutation is a potential predictive biomarker for immunotherapy success, whereas another mechanistic study found that ARID1A-loss results in a cold TIME that is less amenable to immunotherapy. Considering this controversy, our overarching objective is to use multiple high-dimensional microscopy-based techniques to robustly and comprehensively characterize the TIME sculpted by ARID1A-loss. We study this in the context of gastric cancer, a disease which has heterogenous responses to PD-1 based immunotherapy and also shows frequent (10-25%) mutations in ARID1A. We looked at two retrospective cohorts with 250 patients each, one from UK (Leeds) and one from Japan (KCCH). To ascertain ARID1A-loss in these patients, we have set up an IHC-based assay comparing ARID1A expression between tumor and stroma regions. From this, we derive a ratio. In both studies, we were able to clearly stratify the cohort into ARID1A-loss and ARID1A-wildtype. Leeds had about 23 cases (10%) of ARID1A-loss, while KCCH had 39 cases (17.9%). Looking at the clinical parameters, we realized that ARID1A-loss does not stratify for survival nor staging of the tumor, which is also seen in ARID1A-mutation studies. Using multiplex immunohistochemistry (IHC), we saw differences in the immune cell population. ARID1A-loss patients seem to have a greater proportion of CD3+ cells in the Leeds (1423 vs 666 cells/mm2, p = 0.0269) and KCCH cohorts (1457 vs 1268 cells/mm2, p = 0.1745). Interestingly, CD68+ cells also show an increase in the ARID1A-loss population in the Leeds (802.1 cells/mm2 vs 580.3 cells/mm2, p = 0.0649) and KCCH cohorts (659 vs 623.2 cells/mm2). However, CD20+ cells show no changes in abundance for either cohort (249.1 vs 193.2 cells/mm2, p = 0.4985; and 361.6 vs 357.5 cells/mm2, p = 0.9634) respectively. Overall, there seems to be an increase in the T-cell population in ARID1A-loss tumors and an increase in the macrophage population in stroma regions of ARID1A-loss tumors. The B-cell population remains unchanged. To complement our preliminary findings, we will leverage hyperplex and spatial transcriptome techniques to uncover the interactions between tumor cells and the TIME. Citation Format: Norbert Sheng Cong Tay, Yan Fen Peng, Heike Grabsch, Anand D. Jeyasekharan. Spatial characterisation of the tumour immune microenvironment in ARID1A-deficient gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6526.

Supplemental Figure S3 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance

Supplemental Figure S2 from Loss of <i>arid1a</i> Activates <i>anxa1</i>, Which Serves As a Predictive Biomarker for Trastuzumab Resistance

Supplemental Figure S5 from Loss of <i>arid1a</i> Activates <i>anxa1</i>, Which Serves As a Predictive Biomarker for Trastuzumab Resistance

Supplemental Table S1 from Loss of <i>arid1a</i> Activates <i>anxa1</i>, Which Serves As a Predictive Biomarker for Trastuzumab Resistance

Loss of ARID1A Activates ANXA1, Which Serves As a Predictive Biomarker for Trastuzumab Resistance

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Table 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Pan-cancer Analysis of ARID1A Alterations As Biomarkers for Immunotherapy Outcomes

Prognostic role of transcription factor ARID1A in patients with endometrial cancer of no specific molecular profile (NSMP) subtype

Artemin, a Member of the Glial Cell Line-derived Neurotrophic Factor Family of Ligands, Is HER2-regulated and Mediates Acquired Trastuzumab Resistance by Promoting Cancer Stem Cell-like Behavior in Mammary Carcinoma Cells

Abstract 2493: Inactivation of ARID1A-SWI/SNF complex alters chromatin compactness at enhancer regions and affects transcription of key tumor signaling circuitry

Expression of ARID1B is Associated with Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma

Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease

Evaluation of ARID1A as a Potential Biomarker for Predicting Response to Immune Checkpoint Inhibitors in Patients with Endometrial Cancer

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

Abstract 6526: Spatial characterisation of the tumour immune microenvironment in ARID1A-deficient gastric cancer

Prediction of Key Genes and Pathways Involved in Trastuzumab-Resistant Gastric Cancer

Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation

Clinicopathologic and Prognostic Relevance of ARID1A Protein Loss in Colorectal Cancer.

ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance

Integrative analysis of patient-derived tumoroids and ex vivo organoid modeling of ARID1A loss in bladder cancer reveals therapeutic molecular targets